Researcher profile

Charles Brenner, PhD

He identified NR as an NAD precursor with its own salvage pathway, which is the finding the entire NAD supplement category descends from.

Role
Biochemist; discovered the nicotinamide riboside kinase pathway
Affiliation
City of Hope
Topics
NAD · NR vs NMN · Sirtuins
Their work

Why we quote Brenner

He identified NR as an NAD precursor with its own salvage pathway, which is the finding the entire NAD supplement category descends from.

Charles Brenner, PhD is one of the researchers quoted here; the others quoted alongside Charles are listed with the same disclosures.

Where they stand, and who pays

Advises a nicotinamide riboside manufacturer, and is simultaneously one of the harshest public critics of the sirtuin longevity hypothesis and of NMN's absorption claims. Both facts belong next to every quote.

Stating this next to the quote rather than at the bottom of a disclosures page is the whole point. A concession made against a commercial interest is stronger evidence than a neutral summary; a claim made in line with one is weaker. You cannot weigh either without knowing which you are reading.

Every line below is transcribed from a public recording and linked back to it. Nothing here is paraphrased, and Brenner has no relationship with this site.

Everything we quote them saying

All 2 lines, verbatim, in the order they appear in the site's citation index. Each one links to the recording and to the page it is used on.

I don't think that people really have to go higher than a gram.

Charles Brenner, PhD(profile) City of Hope, advisor to an NR maker Modern Healthspan, 2025

Used on NMN Dosage: What the Trials Used and What Nobody Established

The addition of resveratrol to nicotinamide riboside degraded the positive effects of nicotinamide riboside on the six-minute walk test.

Charles Brenner, PhD(profile) City of Hope, advisor to an NR maker Modern Healthspan, 2025

Used on Longevity Supplement Stacks: Combining Unproven Things , Resveratrol and NAD: The Stack Built on a Contested Assay

Pages this research informs

Each page below cites this researcher directly, so you can see the claim a quote supports in its full context.

The standing disclaimer

Charles Brenner, PhD has no relationship with Rapamycin.store and does not endorse anything on it.

  • They have not reviewed this site or any page that quotes them.
  • Quotes are used under fair dealing for criticism and review, each linked to its public recording so you can hear the full context.
  • If a quote here misrepresents what was said, tell us and we will correct it. That correction goes to the front of the queue.

Researchers who want to set out a position in their own words, rather than be quoted, can write for the desk directly.

References

3 sources, all link-checked; oldest check

  1. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. International Committee of Medical Journal Editors, updated 2025.The conflict-of-interest and authorship conventions this desk follows for a lay publication.Verified Sep 14, 2026
  2. PubMed. US National Library of Medicine, National Institutes of Health.The index every citation on this site is checked against before publication.Verified Sep 14, 2026
  3. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Guyatt GH et al. BMJ 2008;336:924.The framework behind the strong / mixed / limited evidence grades used across this site.Verified Sep 14, 2026

Every link above is re-requested on a schedule by an automated checker; the date shown is when it last answered. Publishers that block automated requests are marked as such rather than reported broken. Our editorial standards explain how a source gets cited here in the first place.

Filed by the Rapamycin.store evidence desk. Each source is re-checked when the page is reviewed.

Own a longevity or health brand?

Rapamycin.store publishes sponsored and guest posts on an aged, topically-relevant domain, and offers display advertising. Tell us what you want to promote and we'll send our current options.